Anti-CD59 antibody [MEM-43] (ab9182)

Mouse monoclonal CD59 antibody [MEM-43]. Validated in WB, IP, IHC, Flow Cyt, ICC/IF and tested in Human. Cited in 15 publication(s). Independently reviewed in 2 review(s).

Overview

  • Product name
    Anti-CD59 antibody [MEM-43]
    See all CD59 primary antibodies
  • Description
    Mouse monoclonal [MEM-43] to CD59
  • Host species
    Mouse
  • Specificity
    CD59 antigen (human). MEM-43 identified CD59 as the new cluster on 4th HLDA Workshop. MEM-43 reacts with well defined epitope (WhO, P-53).
  • Tested applications
    Suitable for: IHC-Fr, WB, IP, Flow Cyt, ICC/IF, IHC-Pmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Thymocytes and T lymphocytes.

  • Positive control
    • ICC/IF: Human fibrosarcoma cells. Flow Cyt: HT1080 cells.
  • General notes

    When originally tested in WB, SDS was included in the sample buffer, however, feedback from one researcher has shown that it is best to omit SDS from the sample buffer.

Properties

Applications

Our Abpromise guarantee covers the use of ab9182 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-Fr Use at an assay dependent concentration.
WB Use at an assay dependent concentration. Use under non-reducing conditions.
IP Use at an assay dependent concentration.
Flow Cyt Use a concentration of 1 - 2 µg/ml.

ab170191 - Mouse monoclonal IgG2a, is suitable for use as an isotype control with this antibody.

 

ICC/IF Use at an assay dependent concentration. PubMed: 17911601
IHC-P Use a concentration of 10 µg/ml. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.

Target

  • Function
    Potent inhibitor of the complement membrane attack complex (MAC) action. Acts by binding to the C8 and/or C9 complements of the assembling MAC, thereby preventing incorporation of the multiple copies of C9 required for complete formation of the osmolytic pore. This inhibitor appears to be species-specific. Involved in signal transduction for T-cell activation complexed to a protein tyrosine kinase.
    The soluble form from urine retains its specific complement binding activity, but exhibits greatly reduced ability to inhibit MAC assembly on cell membranes.
  • Involvement in disease
    Defects in CD59 are the cause of CD59 deficiency (CD59D) [MIM:612300].
  • Sequence similarities
    Contains 1 UPAR/Ly6 domain.
  • Post-translational
    modifications
    N- and O-glycosylated. The N-glycosylation mainly consists of a family of biantennary complex-type structures with and without lactosamine extensions and outer arm fucose residues. Also significant amounts of triantennary complexes (22%). Variable sialylation also present in the Asn-43 oligosaccharide. The predominant O-glycans are mono-sialylated forms of the disaccharide, Gal-beta-1,3GalNAc, and their sites of attachment are probably on Thr-76 and Thr-77. The GPI-anchor of soluble urinary CD59 has no inositol-associated phospholipid, but is composed of seven different GPI-anchor variants of one or more monosaccharide units. Major variants contain sialic acid, mannose and glucosamine Sialic acid linked to an N-acetylhexosamine-galactose arm is present in two variants.
    Glycated. Glycation is found in diabetic subjects, but only at minimal levels in nondiabetic subjects. Glycated CD59 lacks MAC-inhibitory function and confers to vascular complications of diabetes.
  • Cellular localization
    Cell membrane. Secreted. Soluble form found in a number of tissues.
  • Information by UniProt
  • Database links
  • Alternative names
    • 16.3A5 antibody
    • 1F5 antibody
    • 1F5 antigen antibody
    • 20 kDa homologous restriction factor antibody
    • CD 59 antibody
    • CD_antigen=CD59 antibody
    • CD59 antibody
    • CD59 antigen antibody
    • CD59 antigen complement regulatory protein antibody
    • CD59 antigen p18 20 antibody
    • CD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344) antibody
    • CD59 glycoprotein antibody
    • CD59 molecule antibody
    • CD59 molecule complement regulatory protein antibody
    • CD59_HUMAN antibody
    • Cd59a antibody
    • Complement regulatory protein antibody
    • EJ16 antibody
    • EJ30 antibody
    • EL32 antibody
    • FLJ38134 antibody
    • FLJ92039 antibody
    • G344 antibody
    • HRF 20 antibody
    • HRF-20 antibody
    • HRF20 antibody
    • Human leukocyte antigen MIC11 antibody
    • Ly 6 like protein antibody
    • Lymphocytic antigen CD59/MEM43 antibody
    • MAC inhibitory protein antibody
    • MAC IP antibody
    • MAC-inhibitory protein antibody
    • MAC-IP antibody
    • MACIF antibody
    • MACIP antibody
    • MEM43 antibody
    • MEM43 antigen antibody
    • Membrane attack complex (MAC) inhibition factor antibody
    • Membrane attack complex inhibition factor antibody
    • Membrane inhibitor of reactive lysis antibody
    • MGC2354 antibody
    • MIC11 antibody
    • MIN1 antibody
    • MIN2 antibody
    • MIN3 antibody
    • MIRL antibody
    • MSK21 antibody
    • p18 20 antibody
    • Protectin antibody
    • Surface antigen recognized by monoclonal antibody 16.3A5 antibody
    • T cell activating protein antibody
    see all

Images

  • Human fibrosarcoma cells stained for CD59 (red) using ab9182 at 10 µg/ml in ICC/IF, followed by Donkey anti-Mouse Alexa 555 at 1/500 dilution.

    See Abreview

  • ab9182 staining CD59 in Human fibrosarcoma (HT1080) by Flow Cytometry. Cells were fixed with paraformaldehyde. The  sample was incubated with the primary antibody,10 µg/ml in PBS, for 1 hour at 20°C. An Abcam PE-conjugated donkey polyclonal to mouse IgG ( ab7003), 5 µg/ml, was used as secondary antibody.

    See Abreview

References

This product has been referenced in:
  • Wang Y  et al. Effect of membrane-bound complement regulatory proteins on tumor cell sensitivity to complement-dependent cytolysis triggered by heterologous expression of the a-gal xenoantigen. Oncol Lett 15:9061-9068 (2018). Read more (PubMed: 29805637) »
  • Wang Y  et al. CD55 and CD59 expression protects HER2-overexpressing breast cancer cells from trastuzumab-induced complement-dependent cytotoxicity. Oncol Lett 14:2961-2969 (2017). Read more (PubMed: 28928834) »
See all 15 Publications for this product

Customer reviews and Q&As

Filter by Application

Filter by Species

Filter by Ratings

1-2 of 2 Abreviews

Application
Flow Cytometry
Sample
Human Cell (Fibrosarcoma (HT1080))
Specification
Fibrosarcoma (HT1080)
Fixation
Paraformaldehyde
Permeabilization
No
Gating Strategy
no gating

Abcam user community

Verified customer

Submitted Aug 13 2009

Application
Immunocytochemistry/ Immunofluorescence
Sample
Human Cell (fibrosarcoma)
Specification
fibrosarcoma
Fixative
Paraformaldehyde
Permeabilization
No

Abcam user community

Verified customer

Submitted Aug 19 2008

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up